JP2012504603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504603A5 JP2012504603A5 JP2011530047A JP2011530047A JP2012504603A5 JP 2012504603 A5 JP2012504603 A5 JP 2012504603A5 JP 2011530047 A JP2011530047 A JP 2011530047A JP 2011530047 A JP2011530047 A JP 2011530047A JP 2012504603 A5 JP2012504603 A5 JP 2012504603A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- autoimmune
- medicament
- manufacture
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000005931 immune cell recruitment Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 206010025130 Lupus encephalitis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19482908P | 2008-10-01 | 2008-10-01 | |
| US61/194,829 | 2008-10-01 | ||
| PCT/US2009/005406 WO2010039236A1 (en) | 2008-10-01 | 2009-10-01 | Compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504603A JP2012504603A (ja) | 2012-02-23 |
| JP2012504603A5 true JP2012504603A5 (enExample) | 2012-11-15 |
Family
ID=41382113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530047A Pending JP2012504603A (ja) | 2008-10-01 | 2009-10-01 | 炎症および免疫関連の使用のための化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20110118281A9 (enExample) |
| EP (1) | EP2350004A1 (enExample) |
| JP (1) | JP2012504603A (enExample) |
| AU (1) | AU2009300316A1 (enExample) |
| CA (1) | CA2739321A1 (enExample) |
| TW (1) | TW201018666A (enExample) |
| WO (1) | WO2010039236A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| CN102971304A (zh) * | 2010-02-01 | 2013-03-13 | 日本化学医药株式会社 | Gpr119激动剂 |
| US20130289071A1 (en) * | 2010-11-09 | 2013-10-31 | Synta Pharmaceuticals Corp. | Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses |
| ES2660996T3 (es) * | 2011-05-03 | 2018-03-27 | PRCL Research Inc. | Compuestos para la inflamación y usos relacionados con el sistema inmunitario |
| CA2868164A1 (en) * | 2012-04-13 | 2013-10-17 | Mitsubishi Tanabe Pharma Corporation | Amidopyridine derivative and use thereof |
| WO2015127284A2 (en) | 2014-02-21 | 2015-08-27 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| WO2015187827A1 (en) * | 2014-06-03 | 2015-12-10 | The Trustees Of The University Of Pennsylvania | Novel effective antiviral compounds and methods using same |
| CN113557020A (zh) | 2018-09-14 | 2021-10-26 | 瑞真药业公司 | 包含crac抑制剂和皮质类固醇的组合物及其使用方法 |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007087443A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| CA2669695C (en) * | 2006-11-13 | 2012-10-30 | Synta Pharmaceuticals Corp. | Tetrahydropyridinyl compounds for inflammation and immune-related uses |
| CA2695156A1 (en) * | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
-
2009
- 2009-10-01 JP JP2011530047A patent/JP2012504603A/ja active Pending
- 2009-10-01 EP EP09789387A patent/EP2350004A1/en not_active Withdrawn
- 2009-10-01 CA CA2739321A patent/CA2739321A1/en not_active Abandoned
- 2009-10-01 TW TW098133369A patent/TW201018666A/zh unknown
- 2009-10-01 AU AU2009300316A patent/AU2009300316A1/en not_active Abandoned
- 2009-10-01 US US12/572,079 patent/US20110118281A9/en not_active Abandoned
- 2009-10-01 WO PCT/US2009/005406 patent/WO2010039236A1/en not_active Ceased
-
2012
- 2012-01-17 US US13/351,351 patent/US20120183579A1/en not_active Abandoned
-
2013
- 2013-07-03 US US13/935,206 patent/US20130303542A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504603A5 (enExample) | ||
| JP2012504604A5 (enExample) | ||
| JP2010535215A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| HRP20171610T1 (hr) | Selektivni inhibitori pi3k delta | |
| US10766900B2 (en) | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof | |
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2017525753A5 (enExample) | ||
| JP2011526244A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| HRP20140541T1 (hr) | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila | |
| JP2005511722A5 (enExample) | ||
| JP2016128501A5 (enExample) | ||
| JP2009110845A5 (enExample) | ||
| JP2011502645A5 (enExample) | ||
| JP2017516785A5 (enExample) | ||
| CA2047390A1 (en) | Carbocyclic analogs of certain nucleosides | |
| EP2909217B1 (en) | Method of preparing halogenated silahydrocarbylenes | |
| JP2013136737A5 (enExample) | ||
| JP2007506765A5 (enExample) | ||
| Akhtar et al. | Deposition of phase pure nickel sulfide thin films from bis (O-alkylxanthato)–nickel (II) complexes by the aerosol assisted chemical vapour deposition (AACVD) method | |
| JP2017513913A5 (enExample) | ||
| WO2012024625A3 (en) | Novel synthesis of nucleoside 5 ' -triphosphates and their derivatives |